Fundamental Analysis

Ratin DSIJ / 14 May 2026 / Categories: Flash News Investment App, Recommendations

1 stock recommendation each based on Fundamental and Technical analysis along with timely review to provide you with handsome profits.

1 stock recommendation each based on Fundamental and Technical analysis along with timely review to provide you with handsome profits. [EasyDNNnews:PaidContentStart]

BIOCON LIMITED
Ticker: 532523
BUY: ₹418.00
Target: ₹465

Biocon Limited is a global biopharmaceutical company with operations across biosimilars, generics and CRDMO. In FY26, the company completed the integration of Biocon Biologics, creating one unified global biopharma platform. The management indicated that the major investment phase across biosimilars, insulins, peptides and complex generics is largely complete, with focus now shifting towards better capacity utilisation, margin expansion and RoCE improvement. Financially, Biocon reported Q4 FY26 revenue from operations of Rs 4,517 crore, up 10 per cent YoY on an adjusted basis and 8 per cent QoQ Total revenue stood at Rs 4,569 crore. EBITDA came in at Rs 1,073 crore, growing 29 per cent year-onyear on an adjusted basis and 13 per cent quarter-on-quarter, with an EBITDA margin of 23 per cent. Profit before Tax before exceptional items stood at Rs 328 crore, while net profit before exceptional items was Rs 179 crore. Given the company’s growth potential, we recommend BUY.

[EasyDNNnews:PaidContentEnd] [EasyDNNnews:UnPaidContentStart]

To read the entire article, you must be a FNI Weekly Subscriber.

[EasyDNNnews:UnPaidContentEnd]